N'-羟基-2,2-二甲基丙脒 | 42956-75-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N'-羟基-2,2-二甲基丙脒
• 中文别名: N'-羟基-2,2-二甲基丙酰胺
• 英文名称: N'-hydroxypivalimidamide
• 英文别名: 2,2-dimethylpropionamidoxime；tert-butylamidoxime；N'-hydroxy-2,2-dimethylpropanimidamide
• CAS: 42956-75-2
• 化学式: C₅H₁₂N₂O
• mdl: MFCD00464113
• 分子量: 116.163
• InChiKey: CVOGFMYWFRFWEQ-UHFFFAOYSA-N

物化性质

• 熔点：
  113-115°

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2925290090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H312,H315,H319,H332,H335
• 储存条件：
  存储条件：2-8°C，避光保存，干燥密封。

SDS

Name:	n -Hydroxy-2 2-dimethylpropanimidamide Material Safety Data Sheet
Synonym:	None Known
CAS:	42956-75-2

Section 1 - Chemical Product MSDS Name:n -Hydroxy-2 2-dimethylpropanimidamide Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
42956-75-2	n'-Hydroxy-2,2-dimethylpropanimidamide	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 42956-75-2: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 115 - 117 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H12N2O
Molecular Weight: 116.16

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Acid chlorides, strong acids, strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 42956-75-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
n'-Hydroxy-2,2-dimethylpropanimidamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 42956-75-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 42956-75-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 42956-75-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N'-羟基-2,2-二甲基丙脒 在 硫酰氟 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以82.4 mg的产率得到tert-butyl cyanamide
  参考文献：
  名称：

  通过SO2F2激活的Tiemann重排将腈（RCN）直接转化为氰胺（RNHCN）的级联过程。

  摘要：

  最近发现了一种简单，温和且实用的腈直接转化为氰胺的方法，该方法具有广泛的底物范围和强大的官能团耐受性（36个实例）。在这种有效的策略中，从腈与羟胺的反应中获得的原位生成的氨基肟，随后进行了Tiemann重排，在SO2F2下以高分离产率生产了相应的氰酰胺。另外，据报道，对照实验阐明了参与形成和消除关键中间体磺酰酯的初步机制。

  DOI：

  10.1039/c9ob01547g
• 作为产物：
  描述：

  三甲基乙腈 在 羟胺 作用下， 以 乙腈 为溶剂， 反应 3.0h， 生成 N'-羟基-2,2-二甲基丙脒
  参考文献：
  名称：

  SO2F2介导的醛（RCHO）转化为氰胺（RNHCN）的一锅级联工艺

  摘要：

  开发了一种简单、温和、实用的将醛直接转化为氰胺的级联工艺，具有底物范围广和官能团耐受性好的特点。该方法允许使用绿色氮源以锅、原子和分步经济的方式将容易获得、廉价且丰富的醛转化为高价值的氰胺。该协议将作为在各种复杂分子中安装氰胺部分的强大工具。

  DOI：

  10.1039/d0ra02631j

文献信息

• Thieno-pyrimidine compounds having fungicidal activity
  申请人：Brewster Kirkland William

  公开号：US20070093498A1

  公开（公告）日：2007-04-26

  The present invention relates to thieno[2,3-d]-pyrimidine compounds having fungicidal activity.

  本发明涉及具有杀真菌活性的噻吩[2,3-d]-嘧啶化合物。
• [EN] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES<br/>[FR] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES
  申请人：BAYER AG

  公开号：WO2021028382A1

  公开（公告）日：2021-02-18

  The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式（I）中R1、R2、R3、R4、R5、R6、R7和R8如所定义的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是癌症或与异常AHR信号传导相关的疾病，或与失调免疫反应或其他与异常AHR信号传导相关的疾病有关的情况，作为唯一药剂或与其他活性成分组合使用。
• [EN] PIPERAZINE DERIVATIVES AS MAGL INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE MAGL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019072785A1

  公开（公告）日：2019-04-18

  The invention provides new heterocyclic compounds having general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  这项发明提供了具有一般式（I）的新的杂环化合物，或其药用可接受的盐，其中R1、R2、X、Y1和Y2如本文所述，包括这些化合物的组合物，制造这些化合物的方法以及使用这些化合物的方法。
• Synthesis and characterization of novel bioactive 1,2,4-oxadiazole natural product analogs bearing the <i>N</i>-phenylmaleimide and <i>N</i>-phenylsuccinimide moieties
  作者：Catalin V Maftei、Elena Fodor、Peter G Jones、M Heiko Franz、Gerhard Kelter、Heiner Fiebig、Ion Neda

  DOI：10.3762/bjoc.9.259

  日期：——

  Taking into consideration the biological activity of the only natural products containing a 1,2,4-oxadiazole ring in their structure (quisqualic acid and phidianidines A and B), the natural product analogs 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)pyrrolidine-2,5-dione (4) and 1-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenyl)-1H-pyrrole-2,5-dione (7) were synthesized starting from 4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)aniline (1) in two steps by isolating the intermediates 4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-4-oxobutanoic acid (3) and (Z)-4-(4-(3-tert-butyl-1,2,4-oxadiazol-5-yl)phenylamino)-4-oxobut-2-enoic acid (6). The two natural product analogs 4 and 7 were then tested for antitumor activity toward a panel of 11 cell lines in vitro by using a monolayer cell-survival and proliferation assay. Compound 7 was the most potent and exhibited a mean IC₅₀ value of approximately 9.4 µM. Aniline 1 was synthesized by two routes in one-pot reactions starting from tert-butylamidoxime and 4-aminobenzoic acid or 4-nitrobenzonitrile. The structures of compounds 1, 2, 4, 5 and 6 were confirmed by X-ray crystallography.

  考虑到仅含有1,2,4-噁二唑环结构的天然产物的生物活性（quisqualic酸和phidianidines A和B），从4-(3-tert-丁基-1,2,4-噁二唑-5-基)苯胺（1）出发，通过分离中间体4-(4-(3-tert-丁基-1,2,4-噁二唑-5-基)苯基氨基)-4-氧代丁酸（3）和（Z）-4-(4-(3-tert-丁基-1,2,4-噁二唑-5-基)苯基氨基)-4-氧代丁-2-烯酸（6），合成了两个天然产物类似物1-(4-(3-tert-丁基-1,2,4-噁二唑-5-基)苯基)吡咯烷-2,5-二酮（4）和1-(4-(3-tert-丁基-1,2,4-噁二唑-5-基)苯基)-1H-吡咯-2,5-二酮（7）。然后，对这两个天然产物类似物4和7进行了体外抗肿瘤活性测试，使用单层细胞存活和增殖实验对11种细胞系进行测试。化合物7表现出最强的抗肿瘤活性，平均IC50值约为9.4 µM。苯胺1通过两种途径合成，一种是从tert-丁基氨基甲酰肼和4-氨基苯甲酸或4-硝基苯甲腈出发进行一锅法反应。化合物1、2、4、5和6的结构经X射线晶体学确认。
• Bioisosteric replacement of the pyrazole 3-carboxamide moiety of rimonabant. A novel series of oxadiazoles as CB1 cannabinoid receptor antagonists
  作者：Cheng-Ming Chu、Ming-Shiu Hung、Min-Tsang Hsieh、Chun-Wei Kuo、Suja T. D.、Jen-Shin Song、Hua-Hao Chiu、Yu-Sheng Chao、Kak-Shan Shia

  DOI：10.1039/b807648k

  日期：——

  Based on the bioisosteric replacement of the pyrazole C3-carboxamide of rimonabant with a 5-alkyl oxadiazole ring, a novel class of oxadiazole derivatives with promising biological activity towards CB1 receptors was discovered. Among them, compounds with an alkyl linker containing a strong electron-withdrawing group (e.g., CF3) and a sterically favorable bulky group (e.g., t-butyl) exhibited excellent CB1 antagonism and selectivity, and thus might serve as potential candidates for further development as anti-obesity agents.

  基于利莫那班的吡唑C3-酰胺的生物等排替换为五元氧二氮杂环，发现了一类新型氧二氮杂环衍生物，具有有希望的生物活性，对CB1受体具有活性。其中，含有强吸电子基团（例如，CF3）和立体有利的大体积基团（例如，叔丁基）的烷基链路的化合物表现出优异的CB1拮抗作用和选择性，因此可能作为进一步开发为抗肥胖药物的潜在候选。